Flash drug release from nanoparticles accumulated in the targeted blood vessels facilitates the tumour treatment
Tumour microenvironment hinders nanoparticle transport deep into the tissue precluding thorough treatment of solid tumours and metastatic nodes. We introduce an anticancer drug delivery concept termed FlaRE (Flash Release in Endothelium), which represents alternative to the existing approaches based on enhanced permeability and retention effect. This approach relies on enhanced drug-loaded nanocarrier accumulation in vessels of the target tumour or metastasised organ, followed by a rapid release of encapsulated drug within tens of minutes. It leads to a gradient-driven permeation of the drug to the target tissue. This pharmaceutical delivery approach is predicted by theoretical modelling and validated experimentally using rationally designed MIL-101(Fe) metal-organic frameworks. Doxorubicin-loaded MIL-101 nanoparticles get swiftly trapped in the vasculature of the metastasised lungs, disassemble in the blood vessels within 15 minutes and release drug, which rapidly impregnates the organ. A significant improvement of the therapeutic outcome is demonstrated in animal models of early and late-stage B16-F1 melanoma metastases with 11-fold and 4.3-fold decrease of pulmonary melanoma nodes, respectively.
Top-30
Journals
1
2
3
|
|
Pharmaceutics
3 publications, 11.11%
|
|
International Journal of Pharmaceutics
2 publications, 7.41%
|
|
Advanced healthcare materials
2 publications, 7.41%
|
|
Journal of Nanobiotechnology
1 publication, 3.7%
|
|
Pharmacia
1 publication, 3.7%
|
|
Langmuir
1 publication, 3.7%
|
|
Nanomaterials
1 publication, 3.7%
|
|
Journal of Materials Chemistry B
1 publication, 3.7%
|
|
Nanotechnology
1 publication, 3.7%
|
|
International Journal of Nanomedicine
1 publication, 3.7%
|
|
Measurement: Journal of the International Measurement Confederation
1 publication, 3.7%
|
|
Applied Physics Letters
1 publication, 3.7%
|
|
Aggregate
1 publication, 3.7%
|
|
ACS applied materials & interfaces
1 publication, 3.7%
|
|
Nature Communications
1 publication, 3.7%
|
|
Doklady Biochemistry and Biophysics
1 publication, 3.7%
|
|
Applied Mathematical Modelling
1 publication, 3.7%
|
|
Materials Today Nano
1 publication, 3.7%
|
|
Доклады Российской академии наук Науки о жизни
1 publication, 3.7%
|
|
Journal of Drug Delivery Science and Technology
1 publication, 3.7%
|
|
Advanced Science
1 publication, 3.7%
|
|
Beilstein Journal of Nanotechnology
1 publication, 3.7%
|
|
1
2
3
|
Publishers
1
2
3
4
5
6
|
|
Elsevier
6 publications, 22.22%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 14.81%
|
|
Wiley
4 publications, 14.81%
|
|
Springer Nature
2 publications, 7.41%
|
|
American Chemical Society (ACS)
2 publications, 7.41%
|
|
Pensoft Publishers
1 publication, 3.7%
|
|
Royal Society of Chemistry (RSC)
1 publication, 3.7%
|
|
IOP Publishing
1 publication, 3.7%
|
|
Dove Medical Press
1 publication, 3.7%
|
|
Cold Spring Harbor Laboratory
1 publication, 3.7%
|
|
American Institute of Physics (AIP)
1 publication, 3.7%
|
|
Pleiades Publishing
1 publication, 3.7%
|
|
The Russian Academy of Sciences
1 publication, 3.7%
|
|
Beilstein-Institut
1 publication, 3.7%
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.